RedHill Says Its Oral Antivirals, Opaganib And RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
(RTTNews) - Specialty biopharmaceutical company RedHill Biopharma Ltd. (RDHL) announced Monday the study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib.
These results build on previously reported data on the inhibition of COVID-19, variants of concern and other viruses, and further support their broad-acting, host-directed mechanisms of action.
The company tested RHB-107 and opaganib using a primary human nasal epithelial cell culture model of Omicron BA.5, which was specifically selected due to the high level of SARS-CoV-2 entry factor expression in these cells. The results show that both RHB-107 and opaganib inhibit Omicron sub-variant BA.5 viral replication, which is indicative of antiviral activity.
The development of both opaganib for hospitalized patients and RHB-107 for non-hospitalized patients is ongoing, including ongoing and planned pandemic preparedness research collaborations with US governmental agencies, pivotal Phase 3 trial design and regulatory clearances, and securing of external non-dilutive funding.
Dollar Extends Losses As Markets Cling On To Fed Cut Hopes
U.S. Homebuilder Confidence Edges Slightly Lower In August
Indian Rupee Rises To 2-week High On GST Reforms Push
Canadian Market May Open Slightly Weak
FTSE 100 Slips After Positive Start, Down Marginally
DAX Drifts Lower; Financials Stocks Among Major Losers
DAX Down In Negative Territory In Cautious Trade
